I agree that this site is using cookies. You can find further informations here.
X
Bijou, F.
41  results:
Search for persons X
?
1

A low lymphocyte‐to‐monocyte ratio (LMR) predicts PFS, POD2..:

Mozas, P. ; Ammar, R. Ould ; Chartier, L....
Hematological Oncology.  41 (2023)  S2 - p. 290-291 , 2023
Link: https://doi.org/10.1002/..
 
?
2

ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIE..:

Zinzani, P. L. ; Mayer, J. ; Trotman, J....
Hematological Oncology.  41 (2023)  S2 - p. 119-121 , 2023
Link: https://doi.org/10.1002/..
 
?
3

REALMA: Subset of patients with Marginal Zone Lymphomas fro..:

Bommier, C. ; Donzel, M. ; Rossi, C....
Hematological Oncology.  41 (2023)  S2 - p. 387-388 , 2023
Link: https://doi.org/10.1002/..
 
?
4

RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE I..:

Thieblemont, C. ; Lamy, T. ; Tani, M....
Hematological Oncology.  41 (2023)  S2 - p. 104-106 , 2023
Link: https://doi.org/10.1002/..
 
?
5

P1186: A LARGE FRENCH REAL WORLD MULTICENTRIC PROSPECTIVE C..:

Ghesquieres, H. ; Cherblanc, F. ; Belot, A....
HemaSphere.  6 (2022)  - p. 1072-1073 , 2022
Link: https://doi.org/10.1097/..
 
?
6

P1133: SUB-CUTANEOUS RITUXIMAB INDUCTION FOLLOWED BY SHORT ..:

Cartron, G. ; Bachy, E. ; Tilly, H....
HemaSphere.  6 (2022)  - p. 1023-1024 , 2022
Link: https://doi.org/10.1097/..
 
?
7

S205: ZANUBRUTINIB + OBINUTUZUMAB (ZO) VS OBINUTUZUMAB (O) ..:

Zinzani, P. L. ; Mayer, J. ; Auer, R....
HemaSphere.  6 (2022)  - p. 106-107 , 2022
Link: https://doi.org/10.1097/..
 
?
8

P1162: ZANUBRUTINIB IN OLDER PATIENTS (PTS) WITH RELAPSED/R..:

Opat, S. ; Hu, B. ; Tedeschi, A....
HemaSphere.  6 (2022)  - p. 1049-1050 , 2022
Link: https://doi.org/10.1097/..
 
?
9

Ibrutinib monotherapy for relapse or refractory primary CNS..:

Soussain, C. ; Choquet, S. ; Blonski, M....
European Journal of Cancer.  117 (2019)  - p. 121-130 , 2019
Link: https://doi.org/10.1016/..
 
?
10

OUTCOME OF PATIENTS WITH C‐MYC REARRANGED DIFFUSE LARGE B C..:

Favre, S. ; Botella‐Garcia, C. ; Bijou, F....
Hematological Oncology.  37 (2019)  S2 - p. 355-356 , 2019
Link: https://doi.org/10.1002/..
 
?
11

BRENTUXIMAB‐VEDOTIN AND BENDAMUSTINE IS A FEASIBLE AND EFFE..:

Gallamini, A. ; Schiano de Colella, J. ; Viotti, J....
Hematological Oncology.  37 (2019)  S2 - p. 292-293 , 2019
Link: https://doi.org/10.1002/..
 
?
12

CHARACTERIZATION OF DUVELISIB IN PATIENTS WITH REFRACTORY M..:

Jacobsen, E. ; Ďuraš, J. ; Ardeshna, K....
Hematological Oncology.  37 (2019)  S2 - p. 400-401 , 2019
Link: https://doi.org/10.1002/..
 
?
13

IBRUTINIB ABOVE 79 YEARS OLD FOR CHRONIC LYMPHOCYTIC LEUKEM..:

Calleja, A. ; Branco, B. ; Teste, A....
Hematological Oncology.  37 (2019)  S2 - p. 384-384 , 2019
Link: https://doi.org/10.1002/..
 
?
14

A PHASE II LYSA STUDY OF OBINUTUZUMAB COMBINED WITH LENALID..:

Morschhauser, F. ; Le Gouill, S. ; Feugier, P....
Hematological Oncology.  35 (2017)  S2 - p. 52-53 , 2017
Link: https://doi.org/10.1002/..
 
?
15

The choice of in-hospital or home administration for plerix..:

Chabannon, C ; Bijou, F ; Grouin, J-M...
Bone Marrow Transplantation.  52 (2017)  8 - p. 1212-1214 , 2017
Link: https://doi.org/10.1038/..
 
1-15